🔗 Visit the ClinicalTrials.gov page for NCT01892371
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. | Ther Adv Hematol | 2014 | 1.28 |
| 2 | Targeting FLT3 to treat leukemia. | Expert Opin Ther Targets | 2014 | 1.02 |
| 3 | Novel drugs for older patients with acute myeloid leukemia. | Leukemia | 2014 | 0.99 |
| 4 | New drugs in acute myeloid leukemia. | Ann Oncol | 2016 | 0.88 |
| 5 | 'Acute myeloid leukemia: a comprehensive review and 2016 update'. | Blood Cancer J | 2016 | 0.86 |
| 6 | Midostaurin: an emerging treatment for acute myeloid leukemia patients. | J Blood Med | 2016 | 0.82 |
| 7 | Is targeted therapy feasible in acute myelogenous leukemia? | Curr Hematol Malig Rep | 2014 | 0.79 |
| 8 | Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies. | Front Oncol | 2015 | 0.75 |